Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease

Surgery (United States)

Volumn 156, Issue 6, 2014, Pages 1531-1541

  Livhits, Masha ^a   Li, Ning ^b   Yeh, Michael W ^a   Harari, Avital ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CUSHING SYNDROME; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; KIDNEY SURGERY; LOWEST INCOME GROUP; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PANCREAS SURGERY; PREDICTIVE VALUE; PRIORITY JOURNAL; PRIVATE HOSPITAL; PROSPECTIVE STUDY; REGIONAL METASTASIS; SEX DIFFERENCE; SOCIAL STATUS; SPLEEN SURGERY; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; AGED; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECONDARY; STATISTICAL MODEL; SURVIVAL; TUMOR INVASION; UNITED STATES;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; CALIFORNIA; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84922446907     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.08.047     Document Type: Article

References (24)

1. Proye CA, Armstrong J, Pattou FN. Adrenocorticalcarcinoma: Nonfunctioning and functioning. In: Clark O, Duh QY, Kebebew E, editors. Textbook of endocrine surgery. 2nd ed. Philadelphia: Elsevier Saunders; 2005. p. 604-11.
2. Wandoloski M, Bussey KJ, Demeure MJ. Adrenocortical cancer. Surg Clin North Am 2009;89: 1255-67.
3. Harari A, Inabnet WB 3rd. Malignant pheochromocytoma: A review. Am J Surg 2011;201: 700-8.
4. O'Neill CJ, Spence A, Logan B, Suliburk JW, Soon PS, Learoyd DL, et al. Adrenal incidentalomas: Risk of adrenocortical carcinoma and clinical outcomes. J Surg Oncol 2010;102: 450-3.
5. Grogan RH, Mitmaker E, Vriens MR, Harari A, Gosnell JE, Shen WT, et al. Adrenal incidentaloma: Does an adequate workup rule out surprises? Surgery 2010;148: 392-7.
6. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8: 163-9.
7. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13: 202-6.
8. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab 2006;91: 2027-37.
9. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: A clinician's update. Nat Rev Endocrinol 2011; 7: 323-35.
10. Bourdeau I, MacKenzie-Feder J, Lacroix A. Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes 2013;20: 192-7.
11. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6: 719-26.
12. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322: 1195-201.
13. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001;12: 703-11.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40: 373-83.
15. Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006;140: 914-20; discussion 9-20.
16. Tran TB, Liou D, Menon VG, Nissen NN. Surgical management of advanced adrenocortical carcinoma: A 21-year population-based analysis. Am Surg 2013;79: 1115-8.
17. Terzolo M, Ardito A, Zaggia B, Laino F, Germano A, De Francia S, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine 2012;42: 521-5.
18. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366: 2189-97.
19. Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012;255: 363-9.
20. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, et al. Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12: 667-80.
21. Dy BM, Wise KB, Richards ML, Young WF, Grant CS, Bible KC, et al. Operative intervention for recurrent adrenocortical cancer. Surgery 2013;154: 1292-9; discussion 9.
22. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91: 2650-5.
23. Lebastchi AH, Kunstman JW, Carling T. Adrenocortical carcinoma: Current therapeutic state-of-the-art. J Oncol 2012; 2012: 234726.
24. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg 2006;30: 872-8.